The SAM prostate cancer nuclear medicine market is expected to grow from US$ 30.64 million in 2022 to US$ 52.63 million by 2028; it is estimated to grow at a CAGR of 9.4% from 2022 to 2028.
The rise in PSA levels increases the risk of prostate cancer. PSA levels in the blood are measured in nanograms per milliliter (ng/mL) units. There is no definitive cutoff point that can determine if a man has prostate cancer or not. When assessing whether a man needs further testing, many doctors choose a PSA cutoff of 4 ng/mL or above, while others may advocate starting at a lower level, such as 2.5 or 3. Therefore, testing PSA levels in a man's blood can detect prostate cancer early. Also, a digital rectal exam (DRE) is another approach to detecting prostate cancer. The doctor uses a gloved, lubricated finger to feel the prostate gland during the exam. Regular screening with a well-validated biomarker could lead to quicker detection of localized disease. Furthermore, distinguishing between low-grade and high-grade disease is critical to avoid unnecessary biopsies, undertreatment of serious disease, and overtreatment of indolent disease.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM prostate cancer nuclear medicine market. The SAM prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
SAM Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
SAM Prostate cancer nuclear medicine Market Segmentation
The SAM prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the SAM prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the SAM prostate cancer nuclear medicine market in 2022. Based on PET product, the SAM prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the SAM prostate cancer nuclear medicine market in 2022. Based on end user, the SAM prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the SAM prostate cancer nuclear medicine market in 2022. Based on country, the SAM prostate cancer nuclear medicine market is segmented into Brazil, Argentina, and the rest of SAM. The Brazil segment dominated the SAM prostate cancer nuclear medicine market in 2022.
ImaginAb; Curium; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the SAM prostate cancer nuclear medicine market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 30.64 Million |
| Market Size by 2028 | US$ 52.63 Million |
| CAGR (2022 - 2028) | 9.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South America Prostate Cancer Nuclear Medicine Market is valued at US$ 30.64 Million in 2022, it is projected to reach US$ 52.63 Million by 2028.
As per our report South America Prostate Cancer Nuclear Medicine Market, the market size is valued at US$ 30.64 Million in 2022, projecting it to reach US$ 52.63 Million by 2028. This translates to a CAGR of approximately 9.4% during the forecast period.
The South America Prostate Cancer Nuclear Medicine Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Prostate Cancer Nuclear Medicine Market report:
The South America Prostate Cancer Nuclear Medicine Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Prostate Cancer Nuclear Medicine Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Prostate Cancer Nuclear Medicine Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South America Prostate Cancer Nuclear Medicine Market
